History
Dialybrid S.r.l. is a clinical-stage medical device company developing innovative vascular grafts for hemodialysis and other vascular applications. Its lead product, Silkothane® Arteriovenous Graft, is based on Silkothane®, a proprietary hybrid material combining silk fibroin and polyurethane. Following the successful completion of preclinical studies on the product, Dialybrid initiated a first-in-human clinical study on Silkothane® Arteriovenous Graft, marking a key milestone in the company’s development and bringing its technology closer to patients and future clinical adoption.
The company raised a €15 million series A round in the summer of 2026, led by specialist life science investor XGEN Venture, with the participation of CDP Venture Capital (Fondo Rilancio), to fund the clinical validation of Dialybrid’s Silkothane® Arteriovenous Graft as a hemodialysis vascular access, and the preclinical development of the proprietary Silkothane® material in other vascular applications.
Dialybrid was founded in August 2020 through the strategic and financial partnership between LIFTT, the investment operating company founded by Fondazione Compagnia di San Paolo and Politecnico di Torino, Bioengineering Laboratories S.r.l. (“BEL”), a medical device company controlled by Delta Med S.p.A. (part of Numantec Group), and Francesco Greco, former Founder & CEO of BEL. The company’s shareholder base was subsequently strengthened by the entry of Como Venture as an investor.

Mission
Dialybrid inherits the R&D experience of Bioengineering Laboratories Srl in relation to Advanced Materials, with the aim of developing a novel semi-degradable vascular access for hemodialysis, based on silk fibroin and polyurethane (an innovative material called Silkothane®).
Team
Founder, President & Chief Executive Officer

Francesco Greco is Founder, Chairman and Chief Executive Officer of Dialybrid. Founder and CEO of BEL since 2001, Francesco is an experienced entrepreneur and a pioneer in Biomedical Engineering in Italy. A graduate of Politecnico di Milano (1982), he has worked for several leading Italian companies in the field of disposable medical devices, and he has founded and led two companies in the same field: Medical Technology (1989) and Bioengineering Laboratories (BEL, 2001). Driven by a constant passion for innovation, Francesco is (co-)inventor of around 20 patent applications, and he has helped bring to market several product lines such as urodynamic catheters and hemodialysis catheters. With a relentless drive for renewal, Francesco has invested substantial resources in highly skilled personnel to develop advanced nanostructured materials made of natural and synthetic polymers, such as Silkothane®. He is co-inventor of the patent behind Dialybrid’s technology.
Chief Technology Officer

Stefania A. Riboldi is Chief Technology Officer at Dialybrid. R&D Manager at BEL from 2008 to 2020, Stefania earned a degree with honors in Biomedical Engineering and a Ph.D. in Tissue Engineering from Politecnico di Milano, with internships at the Department of Materials/Polymers of ETH Zürich. Her academic research focused on the development of novel scaffolds and bioreactors for tissue engineering, specifically polyurethanes and electrospinning technology. At BEL, she dedicated herself to the strategic and operational development of business activities, and to the translation of research ideas into products. In 2012 and 2016, her passion for innovation resulted in her co-inventorship of two patents in the field of Regenerative Medicine, one of which forms the basis of Dialybrid’s innovative vascular access for hemodialysis. She has co-authored more than 15 scientific papers published in international peer-reviewed journals.
Product Engineers

Alice Caldiroli is Product Development Manager at Dialybrid. She earned a degree in Biomedical Engineering from Politecnico di Milano in 2020, completing her Master’s thesis in collaboration with Bioengineering Laboratories Srl (BEL). Her work focused on the manufacturing and the mechanical and morphological characterization of vascular prostheses composed of electrospun Silkothane®, the hybrid material at the core of of Dialybrid’s innovative technology for hemodialysis. After graduating, Alice continued her research on Silkothane® at Bioengineering Laboratories on both medium and small caliber grafts, which resulted in two journal publications and congress presentations. Since 2022, Alice has been part of Dialybrid’s team, involved in the crucial translational phase that will lead Silkothane® products from basic research to industrialization.

Federica Barzaghi is Production Manager at Dialybrid. She earned a degree in Biomedical Engineering from Politecnico di Milano in April 2024, completing her Master’s thesis in collaboration with Dialybrid. Her work mainly focused on the in vitro characterization of Silkothane® Arteriovenous Grafts, with an emphasis on the study of their degradation products. After graduating, Federica has continued her research through an internship split between Dialybrid and Politecnico di Milano, studying new methods for the processing of silk fibroin and novel techniques for its characterization.
R&D Engineers

Cristina Oldani is R&D Manager at Dialybrid. She earned a degree in Biomedical Engineering from Politecnico di Milano in 2021, completing her Master’s thesis in collaboration with Istituto Italiano di Tecnologia (IIT). Her work focused on producing and characterizing microgels made of silk fibroin, the same material that constitutes the core of Dialybrid’s technology. After graduating, Cristina started an internship at the R&D department of Tissium, a French biomedical company that develops devices for nerve regeneration. In 2022, Cristina joined Dialybrid’s team and concurrently started a Bioengineering Executive Ph.D. program at Politecnico di Milano, sponsored by the company. Her role, split between Dialybrid and the university, is to contribute to the basic research involved in validating the Silkothane® products and their translation to market.
Business Developer

Tommaso Proserpio is Business Developer at Dialybrid. He holds a Master’s degree in Banking, Markets and Corporate Finance from LIUC – Università Cattaneo. He joined Dialybrid in 2023, supporting the company in financial planning, business planning and business development activities. His work mainly focuses on financial monitoring, budgeting and forecasting, preparation of periodic investor reporting, and development of financial models to support management decisions. He also supports financial due diligence and fundraising activities, as well as the preparation of financial information and materials for investors and other stakeholders.
Scientific Advisory Board

Matteo Tozzi graduated cum laude in Medicine and Surgery at the University “La Sapienza” of Rome in 2001, Dr. Tozzi specialized cum laude in Vascular Surgery in 2006 at the University of Insubria, Varese. Since 2014, he is Associate Professor of Vascular Surgery at the same University. He is Director of the Research Center for the Study and Application of New Technologies in Vascular Surgery and of the Research Center for the Study and Development of Organ Transplants at the University of Insubria since October 2017. Dr. Tozzi is member of SICVE – Società Italiana di Chirurgia Vascolare ed Endovascolare, member of the Council of VAS – Vascular Access Society, and author of several scientific publications in the vascular and vascular accesses field. Of note, he is one of the major experts in Italy as regards early-cannulation grafts for hemodialysis.

Luciano Carbonari graduated in Medicine and Surgery at the University of Ancona in 1980, Dr. Carbonari specialized in General Surgery in 1985 and in Vascular Surgery in 1997 at the same University. He worked as Medical Director of the Vascular Surgery Unit at Ospedali Riuniti of Ancona from 1993 to 2006, and since then he is Head of the same Unit. Since 2000 he is in charge of the regional center for vascular access in the Marche Region and collaborator of the study group of the Italian Society of Nephrology. Also Responsible for the Management of his Unit since 2003, Luciano served as medical consultant for Bioengineering Laboratories as regards hemodialysis vascular accesses from 2015 to 2020. He is member of the Italian Society of Vascular Surgery and of the European Society for Vascular Surgery and he is author and co-author of several scientific publications in the vascular field.

Franco Galli graduated in Medicine and Surgery at the University of Pavia in 1973, Dr. Galli specialized in Biomedical Technologies at the University of Bologna in 1992. He worked as Medical Director at the Division of Nephrology and Dialysis of the S. Maugeri Foundation in Pavia from 1974 to 2009 and he was Head of Vascular Access Surgery for Hemodialysis at this Division from 2000 to 2009. Consultant for Bioengineering Laboratories Srl since 2001, Franco Galli is member of the Italian Society of Nephrology (SIN), member of the Vascular Access Society (VAS), member of the Editorial Board of the Journal of Vascular Access – SAGE, Member of the Editorial Board of the Journal of Nephrological and Dialytic Techniques – SAGE. He is author and co-author of numerous scientific publications in the nephrological field.
Board of Directors

Francesco Greco, President of the Board, Founder & CEO
Serial MedTech entrepreneur, biomedical engineer and co-inventor of 20+ patents.

Daniele Timothy Scarinci, Board Director
Co-Founder & Managing Partner at XGEN Venture, with 20+ years of experience in Life Sciences Venture Capital.

Luca Porro, Board Director
MedTech Specialist at XGEN Venture, with 20 years of experience in MedTech as a corporate manager, advisor and investor.

Marco Dieci, Board Director
Senior Partner at CDP Venture Capital, with 25+ years of experience in Life Sciences Venture Capital.
Medical Advisory Board
Currently being established, the MAB will include leading international experts in vascular surgery and nephrology, providing strategic guidance on Dialybrid’s clinical, regulatory and scientific development.
